BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis

International Journal of Gynecological Cancer

Volumn 22, Issue SUPPL. 1, 2012, Pages

  Crum, Christopher P ^a   McKeon, Frank D ^a   Xian, Wa ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BRCA; Fallopian tube; Ovarian cancer; P53; P53 signature; Serous cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P16; PROTEIN P53; TRANSCRIPTION FACTOR PAX2; WT1 PROTEIN;

CANCER PREVENTION; CARCINOGENESIS; CELL GROWTH; CONFERENCE PAPER; ENDOMETRIOID CARCINOMA; FIMBRIA; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; SECRETORY CELL; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; UTERINE TUBE CARCINOMA;

CARCINOMA IN SITU; CELL TRANSFORMATION, NEOPLASTIC; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; HUMANS; OVARIAN NEOPLASMS; PAX2 TRANSCRIPTION FACTOR;

EID: 84863673638     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31824d7269     Document Type: Conference Paper

References (51)

1. American Cancer Society. Cancer facts and figures 2012. Available at: http://www.cancer.org/Research/ CancerFactsFigures/index.
2. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. GynecolOncol. 2007;107:159-162. (Pubitemid 47575743)
3. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518. (Pubitemid 38529752)
4. Cannistra SA. Ovarian cancer. N Engl J Med. 2004;351:2519-2529.
5. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol. 2009;3:165-170.
6. Gershenson DM, Tortolero-Luna G, Malpica A, et al. Ovarian intraepithelial neoplasia and ovarian cancer. Obstet Gynecol Clin North Am. 1996;23:475-543. (Pubitemid 26185972)
7. Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors. Gynecol Oncol. 1989;35:236-239. (Pubitemid 19268565)
8. Stewart SL,Wike JM, Foster SL, et al. The incidence of primary fallopian tubecancer in the United States. Gynecol Oncol. 2007;107:392-397. (Pubitemid 350160878)
9. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25:1283-1289. (Pubitemid 32917122)
10. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87:52-56. (Pubitemid 36027101)
11. Powell CB, Kenley E, Chen LM, et al. Risk reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23:127-132. (Pubitemid 41702631)
12. Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006;30:1222-1230. (Pubitemid 44454699)
13. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64. (Pubitemid 41815050)
14. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990. (Pubitemid 47477278)
15. Hirst JE, Gard GB, McIllroy K, et al. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer. 2009;19:826-829.
16. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27:1-9. (Pubitemid 351627965)
17. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169. (Pubitemid 46175016)
18. CarlsonJW, Miron A, JarboeEA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160-4165.
19. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 2008;110:408-417.
20. Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol. 2009;33:376-383.
21. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (non uterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34:1407-1416.
22. Seidman JD, Zhao P, Yemelyanova A. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol. 2011;120:470-473.
23. Leonhardt K, Einenkel J, Sohr S, et al. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol. 2011;30:417-424.
24. Kalloger SE, Köbel M, Leung S, et al. Calculator for ovarian carcinoma subtype prediction. Mod Pathol. 2011;24:512-521.
25. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456. (Pubitemid 33069670)
26. Lee Y,Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35. (Pubitemid 46092026)
27. Hutson R, Ramsdale J, Wells M. P53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology. 1995;27:367-371.
28. Barakat RR, Federici MG, Saigo PE, et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer. 2000;89:383-390. (Pubitemid 30489888)
29. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol. 2008;109:168-173.
30. Cass I, Holschneider C, Datta N, et al. BRCA mutationYassociated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol. 2005;106:1327-1334. (Pubitemid 41668953)
31. Saleemuddin A, Folkins AK, Garrett L, et al. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol Oncol. 2008;111:226-232.
32. Levanon K, Ng V, Piao HY, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. 2010;29:1103-1113.
33. Zeki SS, Graham TA, Wright NA. Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8:90-100.
34. Ito R, Kondo F, Yamaguchi T, et al. Pancreatic intraepithelial neoplasms in the normal appearing pancreas: on their precise relationship with age. Hepatogastroenterology. 2008;55:1103-1106. (Pubitemid 351975995)
35. Epstein JI. Precursor lesions to prostatic adenocarcinoma. Virchows Arch. 2009;454:1-16.
36. Norquist BM, Garcia RL, Allison KH, et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer. 2010;116:5261-5271.
37. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009;22:1133-1138.
38. Mehra K, Mehrad M, Ning G, et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed). 2011;3:625-634.
39. Chen EY, Mehra K, Mehrad M, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol. 2010;222:110-116.
40. Laury AR, Ning G, Quick CM, et al. Fallopian tube correlates of ovarian serous borderline tumors. Am J Surg Pathol. 2011;35:1759-1765.
41. Quick CM, Ning G, Bijron J, et al. PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. Mod Pathol. 2012 (in press).
42. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236. (Pubitemid 43740193)
43. Rabban JT, Krasik E, Chen LM, et al. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009;33:1878-1885.
44. Semmel DR, Folkins AK, Hirsch MS, et al. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol. 2009;22:985-988.
45. Kwon JS, Daniels MS, Sun CC, et al. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol. 2010;28:675-682.
46. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615. (Pubitemid 34755668)
47. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622. (Pubitemid 34755669)
48. Piek JM, Torrenga B, Hermsen B, et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer. 2003;2:73-78. (Pubitemid 37247978)
49. Domchek SM, Gaudet MM, Stopfer JE, et al. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat. 2010;119:409-414.
50. McAlpine JN, El Hallani S, Lam SF, et al. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol Oncol. 2011;120:385-392.
51. Dietl J, Wischhusen J, Häusler SF. The post-reproductive fallopian tube: better removed? Hum Reprod. 2011;26:2918-2924.